维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09887 维立志博-B

交易中 11-12 10:09:59

58.950

-0.400

-0.67%

最高59.450	最低58.150	成交量13.59万
今开59.200	昨收59.350	日振幅2.19%
总市值117.31亿	流通市值90.19亿	总股本1.99亿
成交额800.57万	换手率0.09%	流通股本1.53亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":58.95,"timestamp":1762913349277,"preClose":59.35,"halted":0,"volume":135900,"delay":0,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"交易中","change":-0.4,"latestTime":"11-12 10:09:59","open":59.2,"high":59.45,"low":58.15,"amount":8005715,"amplitude":0.021904,"askPrice":58.95,"askSize":200,"bidPrice":58.9,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-1.858667,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1762920000000},"marketStatusCode":2,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":59.35,"openAndCloseTimeList":[[1762911000000,1762920000000],[1762923600000,1762934400000]],"volumeRatio":2.112856,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09887/","defaultTab":"news","newsList":[{"id":"2582391954","title":"维立志博-B11月11日主力净流出56.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2582391954","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582391954?lang=zh_cn&edition=full","pubTime":"2025-11-11 16:15","pubTimestamp":1762848958,"startTime":"0","endTime":"0","summary":"11月11日, 维立志博-B股价跌0.67%，报收59.35元，成交金额1805.5万元，换手率0.20%，振幅2.85%，量比0.52。维立志博-B今日主力资金净流出56.5万元，上一交易日主力净流入998.5万元。该股近5个交易日上涨5.18%，主力资金累计净流入1146.0万元；近20日主力资金累计净流出524.7万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111116222994fd382c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111116222994fd382c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2582825495","title":"维立志博-B(09887)：LBL-024于一线治疗肝细胞癌II期试验的首例患者用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2582825495","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582825495?lang=zh_cn&edition=full","pubTime":"2025-11-10 16:42","pubTimestamp":1762764148,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，评价奥帕替苏米单抗用于一线治疗肝细胞癌的II期临床研究首例患者已成功用药，标志着该核心产品适应症拓展高效推进。该试验旨在评价奥帕替苏米单抗联合用药一线治疗肝细胞癌患者的疗效及安全性。LBL-024是一种同时靶向PD-L1与4-1BB的双特异性抗体，为针对肺外神经内分泌癌的全球首款达到注册临床阶段的靶向4-1BB受体的疗法。LBL-024亦有望成为治疗晚期肺外神经内分泌癌的首款获批药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367251.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B(09887)：LBL-024于一线治疗肝细胞癌II期试验的首例患者用药","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2582950894","title":"港股公告掘金 | 乐舒适明日上市 富智康集团预期年度财务业绩大幅改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2582950894","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582950894?lang=zh_cn&edition=full","pubTime":"2025-11-09 19:58","pubTimestamp":1762689534,"startTime":"0","endTime":"0","summary":"【重大事项】乐舒适(02698):香港公开发售获1813.77倍认购 预计11月10日上市中伟新材(02579)11月7日至11月12日招股 预计11月17日上市百利天恒(02615)11月7日至11月12日招股 预计11月17日上市昊海生物科技(06826)拟7400万元收购深圳市新产业眼科新技术有限公司余下20%股权维立志博-B(09887)获纳入MSCI全球小型股指数恒瑞医药(01276)：","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1160","LU0359201885.HKD","BK1612","BK1161","BK1531","BK1104","BK1167","LU0359201612.USD","BK1191","LU1023057109.AUD","09887","BK1508","LU0359202008.SGD","02698","LU2543165471.USD","02038","01276","BK1526","00434","BK1504"],"gpt_icon":0},{"id":"2581024901","title":"维立志博-B(09887)获纳入MSCI全球小型股指数","url":"https://stock-news.laohu8.com/highlight/detail?id=2581024901","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581024901?lang=zh_cn&edition=full","pubTime":"2025-11-07 12:06","pubTimestamp":1762488361,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，公司将获纳入MSCI全球小型股指数成份股，自2025年11月24日收市后生效。MSCI全球小型股指数由Morgan Stanley Capital International(MSCI)编制，旨在衡量市场小型股板块的表现。MSCI指数被众多国际专业投资机构广泛参考。董事会认为，公司获纳入MSCI全球小型股指数反映全球投资者对公司经营表现及发展潜力的认可。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","IE00BKPKM429.USD","LU2265009873.SGD","BK1161","LU0511384066.AUD","LU2210150020.SGD","LU0289960550.SGD","LU1267930730.SGD","LU2095319765.USD","LU2210149790.SGD","LU1691799644.USD","LU0109391861.USD","LU0320765059.SGD","LU1804176565.USD","LU0175139822.USD","LU0289961442.SGD","BK4585","LU0390134368.USD","09887","LU0708995401.HKD","MSCI","LU0672654240.SGD","LU0289739343.SGD","BK4112"],"gpt_icon":0},{"id":"2581703741","title":"维立志博-B11月05日获主力加仓39.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581703741","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581703741?lang=zh_cn&edition=full","pubTime":"2025-11-05 16:16","pubTimestamp":1762330566,"startTime":"0","endTime":"0","summary":"11月05日, 维立志博-B股价涨0.63%，报收56.30元，成交金额3181.0万元，换手率0.37%，振幅9.03%，量比0.63。维立志博-B今日主力资金净流入39.3万元，上一交易日主力净流入203.2万元。该股近5个交易日下跌4.24%，主力资金累计净流入480.7万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出874.5万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516232397555819&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516232397555819&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2581716839","title":"维立志博-B(09887.HK)涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581716839","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581716839?lang=zh_cn&edition=full","pubTime":"2025-11-05 11:32","pubTimestamp":1762313547,"startTime":"0","endTime":"0","summary":"每经AI快讯，维立志博-B(09887.HK)涨超3%，截至发稿，涨3.49%，报57.9港元，成交额2020.56万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511053555689937.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511053555689937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2581171560","title":"港股异动 | 维立志博-B(09887)涨超3% 5项血液肿瘤领域研究成果于2025 ASH年会公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2581171560","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581171560?lang=zh_cn&edition=full","pubTime":"2025-11-05 11:20","pubTimestamp":1762312846,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B(09887)涨超3%，截至发稿，涨3.49%，报57.9港元，成交额2020.56万港元。消息面上，11月4日，维立志博-B发布公告，内容有关5篇研究摘要入选美国血液学会以于其第67届年会上展示。公司欣然提供有关其在研创新药 LBL-034及LBL-076的进一步详情，该等药物的多份研究摘要已被第67届ASH年会收录。其中，1项LBL-034临床研究获选在大会首日作第一个口头报告，展示LBL-034对复发╱难治性多发性骨髓瘤患者的最新疗效及安全性数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4109","LU2463526074.USD","ASH","09887"],"gpt_icon":0},{"id":"2580738376","title":"维立志博-B11月04日主力净流入203.2万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2580738376","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580738376?lang=zh_cn&edition=full","pubTime":"2025-11-04 16:15","pubTimestamp":1762244135,"startTime":"0","endTime":"0","summary":"11月04日, 维立志博-B股价涨0.99%，报收55.95元，成交金额3193.8万元，换手率0.37%，振幅6.77%，量比0.64。维立志博-B今日主力资金净流入203.2万元，上一交易日主力净流出70.1万元。该股近5个交易日下跌6.04%，主力资金累计净流入1266.1万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入522.0万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511041618379752f6ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511041618379752f6ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2580622162","title":"维立志博-B(09887)：1项LBL-034临床研究获选在第67届ASH年会首日作第一个口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2580622162","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580622162?lang=zh_cn&edition=full","pubTime":"2025-11-04 06:37","pubTimestamp":1762209451,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，内容有关5篇研究摘要入选美国血液学会以于其第67届年会上展示。公司欣然提供有关其在研创新药 LBL-034及LBL-076的进一步详情，该等药物的多份研究摘要已被第67届ASH年会收录。其中，1项LBL-034临床研究获选在大会首日作第一个口头报告，展示LBL-034对复发╱难治性多发性骨髓瘤患者的最新疗效及安全性数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4109","LU2463526074.USD","ASH","09887"],"gpt_icon":0},{"id":"2580501002","title":"【券商聚焦】信达证券首予维立志博(09887)“买入”评级 指ADC平台未来可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2580501002","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580501002?lang=zh_cn&edition=full","pubTime":"2025-11-03 13:18","pubTimestamp":1762147106,"startTime":"0","endTime":"0","summary":"金吾财讯 | 信达证券研报指出，维立志博 是国内稀缺的同时具备IO2.0+ADC2.0平台的Biotech，在IO联合ADC的大背景下，公司构建的新一代++成为其核心竞争力，基于三大技术平台全面布局 IO2.0、TCE、ADC 三大业界公认的肿瘤治疗前沿技术方向，全方位、多手段攻克肿瘤治疗难题。LBL-024 联合化疗一线治疗肺外神经内分泌癌、一线治疗小细胞肺癌均表现出了“Bestin-Class”竞争力，显著优于现有 SOC。LBL-024 单药治疗有望填补肺外神经内分泌癌末线治疗的空白。ADC平台未来可期。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1968896","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601059","09887","ADC"],"gpt_icon":0},{"id":"2579461869","title":"维立志博-B10月31日主力净流出37.7万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2579461869","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579461869?lang=zh_cn&edition=full","pubTime":"2025-10-31 16:15","pubTimestamp":1761898509,"startTime":"0","endTime":"0","summary":"10月31日, 维立志博-B股价跌5.79%，报收53.70元，成交金额4422.6万元，换手率0.54%，振幅9.47%，量比0.88。维立志博-B今日主力资金净流出37.7万元，上一交易日主力净流入346.0万元。该股近5个交易日下跌14.35%，主力资金累计净流出176.8万元；近20日主力资金累计净流入1614.8万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103116155194e71716&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103116155194e71716&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2579432799","title":"刚刚 20%涨停！重磅消息 引爆！","url":"https://stock-news.laohu8.com/highlight/detail?id=2579432799","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579432799?lang=zh_cn&edition=full","pubTime":"2025-10-31 14:55","pubTimestamp":1761893740,"startTime":"0","endTime":"0","summary":"今日，A股、港股创新药概念股全线爆发，三生国健、舒泰神强势录得20%涨停。消息面上，10月30日，2025年国家医保谈判在北京开启。今年国谈在延续医保目录常规调整机制的基础上，首次正式引入“商保创新药目录”机制。根据国家医保局8月28日公告，2025年基本药品目录调整有535个药品通用名通过形式审查。5年内获批上市的新通用名药品，或治疗罕见病的独家药品可申报商保创新药目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031151209a6d84f76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031151209a6d84f76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161","01801","BK1574","06978"],"gpt_icon":0},{"id":"2579126321","title":"港股创新药调整期真的来了？维立志博董事长康小强：不会将注意力集中于“追风”","url":"https://stock-news.laohu8.com/highlight/detail?id=2579126321","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579126321?lang=zh_cn&edition=full","pubTime":"2025-10-30 22:34","pubTimestamp":1761834886,"startTime":"0","endTime":"0","summary":"今年国庆中秋假期前后，Biotech（生物科技公司）再次在港交所排起了长龙，而错峰递表的维立志博（HK09887，股价57.00港元，市值113.37亿港元）赶在7月完成了公司的“上市礼”。7月25日，当维立志博创始人康小强敲响铜锣，中国“TCE（T细胞衔接器）第一股”就此诞生。在业内，TCE远没有ADC（抗体偶联药物）的名气大。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510303550786512.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510303550786512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","09887","06978","BK1574"],"gpt_icon":0},{"id":"2579150721","title":"港股生物科技板块集体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=2579150721","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579150721?lang=zh_cn&edition=full","pubTime":"2025-10-30 10:08","pubTimestamp":1761790123,"startTime":"0","endTime":"0","summary":"每经AI快讯，10月30日，港股生物科技板块集体走弱，荃信生物-B、维立志博-B跌超10%，荣昌生物、君实生物、药明生物纷纷下挫。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510303549808587.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510303549808587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359202008.SGD","BK4023","LU0516422952.EUR","02269","BK1610","BK1521","LU0516423174.USD","BK4588","IE00B0JY6N72.USD","LU0456846285.SGD","LU1242518857.USD","02509","09887","LU1794554557.SGD","LU0320764599.SGD","LU0417516902.SGD","BK4543","LU3063872942.SGD","LU0327786744.USD","LU1969619763.USD","BK1576","LU0819121731.USD","BK1161","LU0181495838.USD","LU0516422366.SGD","LU0348825331.USD","AI","BK1589","LU0039217434.USD","LU0307460666.USD","LU0326950275.SGD","LU1688375341.USD","LU1720050803.USD","SG9999002562.SGD","BK4551","LU0572944931.SGD","LU2039709279.SGD","LU0140636845.USD","LU0823426480.USD","SG9999002463.SGD","LU0708995583.HKD","LU0979878070.USD","BK1141","LU0516422440.USD","BK4528","LU0456827905.SGD","LU0043850808.USD","09995","LU0516423091.SGD","LU0052750758.USD"],"gpt_icon":0},{"id":"2579768169","title":"超百亿美元大单却带不动股价 创新药BD催化剂失灵？","url":"https://stock-news.laohu8.com/highlight/detail?id=2579768169","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579768169?lang=zh_cn&edition=full","pubTime":"2025-10-29 18:02","pubTimestamp":1761732120,"startTime":"0","endTime":"0","summary":"如今，即便收获了金额百亿美元以上的超“大单”，创新药企业的股价仍旧低迷。股价快速上涨往往伴随关键的消息催化剂。Choice数据显示，2025年上半年，市值达到百亿港元规模的港股上市公司中，仅有3家创新药企的营业收入出现下滑，其余8家企业的营业收入均出现增长。中邮证券分析师盛丽华判断，近期创新药板块持续调整，一方面消化前期涨幅，另一方面BD催化剂较少，博弈情绪退坡。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029180752a47b96ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029180752a47b96ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0502904849.HKD","01801","BK1161","09887","BK1589","LU2097828557.USD","LU2242644610.SGD","06978","BK1574","LU2097828714.EUR","BK1583","LU1969619763.USD","03692","LU2328871848.SGD","LU2097828631.EUR","LU2488822045.USD","LU2097828474.EUR","LU0455707207.USD","LU2097828805.USD"],"gpt_icon":1},{"id":"2578614963","title":"维立志博-B(09887)：LBL-024于一线治疗胆道癌II期试验的首例患者用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2578614963","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578614963?lang=zh_cn&edition=full","pubTime":"2025-10-27 18:11","pubTimestamp":1761559909,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，评价奥帕替苏米单抗用于一线治疗胆道癌的II期临床试验首例患者已成功用药，标志着该核心产品适应症拓展高效推进。LBL-024是一种同时靶向PD-L1与4-1BB的双特异性抗体，为针对肺外神经内分泌癌的全球首款达到注册临床阶段的靶向4-1BB受体的疗法。LBL-024亦有望成为治疗晚期肺外神经内分泌癌的首款获批药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1360491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","BK1161"],"gpt_icon":1},{"id":"2577531442","title":"维立志博-B10月23日主力净流出277.1万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2577531442","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577531442?lang=zh_cn&edition=full","pubTime":"2025-10-23 16:16","pubTimestamp":1761207365,"startTime":"0","endTime":"0","summary":"10月23日, 维立志博-B股价跌2.56%，报收62.70元，成交金额4090.7万元，换手率0.43%，振幅6.68%，量比1.23。维立志博-B今日主力资金净流出277.1万元，上一交易日主力净流入130.1万元。该股近5个交易日下跌5.28%，主力资金累计净流出178.9万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入3852.9万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023162318a6c99ca0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023162318a6c99ca0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2576995709","title":"维立志博-B药品LBL-047成功出海 获3800万美元首付款 潜在收益高达10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576995709","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576995709?lang=zh_cn&edition=full","pubTime":"2025-10-17 10:28","pubTimestamp":1760668126,"startTime":"0","endTime":"0","summary":"维立志博-B（09887）发布公告，公司于2025年10月16日与DianthusTherapeutics,Inc.签订全球独家许可协议，双方将共同推进临床前资产及新型抗BDCA2-TACI双特异性融合蛋白LBL-047的开发。LBL-047已获得美国新药临床试验（IND）许可及中国内地IND受理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510173537019885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09887","BK1161"],"gpt_icon":1},{"id":"2576195700","title":"最高10亿美元！和美国一家生物科技公司签了个“独家授权协议”！","url":"https://stock-news.laohu8.com/highlight/detail?id=2576195700","media":"企业上市","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576195700?lang=zh_cn&edition=full","pubTime":"2025-10-17 10:24","pubTimestamp":1760667892,"startTime":"0","endTime":"0","summary":"核心事件：南京维立志博生物科技公司在2025年10月16日，和美国一家叫Dianthus的生物科技公司签了个“独家授权协议”。维立志博能得到什么：首付款和近期里程碑款：最高3800万美元。其中包括2000万美元的“签字费”，2025年第四季度再付500万美元，以及最高1300万美元的近期研发进展奖金。未来潜在巨额奖金：如果这款药后续的临床开发、审批和商业化都成功了，维立志博最高还能拿到10亿美元的里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017113537a4645d5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017113537a4645d5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2575374928","title":"维立志博-B(09887)就LBL-047与DIANTHUS签订全球独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2575374928","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575374928?lang=zh_cn&edition=full","pubTime":"2025-10-16 20:55","pubTimestamp":1760619343,"startTime":"0","endTime":"0","summary":"本公司认为签订全球独家许可协议将加强本集团推进创新候选药物进入临床阶段以解决自身免疫疾病的承诺，并符合本公司及其股东的整体最佳利益。LBL-047以BAFF/APRIL和BDCA2为靶点，旨在同时抑制pDC的活性以及B细胞及浆细胞的分化及激活。LBL-047通过Fc区改造延长半衰期，可降低给药频次，提高患者依从性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B(09887)就LBL-047与DIANTHUS签订全球独家许可协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leadsbiolabs.com","stockEarnings":[{"period":"1week","weight":0.0608},{"period":"1month","weight":-0.1509},{"period":"3month","weight":-0.1348},{"period":"6month","weight":0.6957},{"period":"ytd","weight":0.6957}],"compareEarnings":[{"period":"1week","weight":0.0287},{"period":"1month","weight":0.0154},{"period":"3month","weight":0.0423},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.3069},{"period":"ytd","weight":0.3308}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京维立志博生物科技股份有限公司是一家主要从事发现、开发和商业化治疗肿瘤、自身免疫性疾病以及其他严重疾病的新疗法的中国公司。该公司的主要候选药物包括LBL-024、LBL-034、LBL-033、LBL-007等。该公司的LBL-024主要用于治疗肺外神经内分泌癌（EP-NEC）、小细胞肺癌（SCLC）、胆道癌（BTC）及非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、肝细胞癌（HCC）、胃癌（GC）及其他实体瘤。该公司还开发了专有技术平台，包括LeadsBody平台（CD3 T-cell engager平台）、X-body平台（4-1BB engager平台）以及其他几个双特异性抗体及融合蛋白平台。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"维立志博-B","nameEN":"LEADS BIOLABS-B"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.5","shortVersion":"4.35.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维立志博-B,09887,维立志博-B股票,维立志博-B股票老虎,维立志博-B股票老虎国际,维立志博-B行情,维立志博-B股票行情,维立志博-B股价,维立志博-B股市,维立志博-B股票价格,维立志博-B股票交易,维立志博-B股票购买,维立志博-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}